<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963260</url>
  </required_header>
  <id_info>
    <org_study_id>8723-001</org_study_id>
    <nct_id>NCT01963260</nct_id>
  </id_info>
  <brief_title>Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)</brief_title>
  <official_title>A Two-Part, Single Rising Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MK-8723 in Healthy Adults and Patients With Immune Thrombocytopenia Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to assess the safety and tolerability of single
      rising doses of MK-8723 in healthy adult participants and adult participants with chronic
      immune thrombocytopenia purpura (ITP) and to assess pharmacodynamics of MK-8723 in
      participants with ITP. The primary hypothesis is that the true placebo-adjusted platelet
      response rate to MK-8723 in adult patients with chronic ITP is &gt;50%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part 1 of the trial, safety and pharmacokinetics of MK-8723 will be evaluated in healthy
      participants. In Part 2 of the trial, safety, pharmacokinetics, and pharmacodynamics will be
      evaluated among participants with ITP. In Part 1, dose escalation will occur in up to 5
      serial panels of participants; each participant will receive a single intravenous (IV) dose
      of MK-8723 (or placebo). In Part 2, dose escalation will occur in up to 3 serial panels of
      participants with ITP; each participant will receive a single IV dose of MK-8723 (or
      placebo), once safety and tolerability of the corresponding dose is shown in Part 1.
      Amendment 3 specified a re-enrollment procedure for eligible participants in Part 2 to
      participate in more than one dosing panel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>An AE is defined as any unfavorable and unintended medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinuing Study Due to an Adverse Event (AE)</measure>
    <time_frame>Up to 84 Days</time_frame>
    <description>An AE is defined as any unfavorable and unintended medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Positive Platelet Response to MK-8723</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>In participants with ITP, platelet response is a rapid, sensitive, and highly qualitative measure of response to anti-inflammatory therapy. A positive platelet response was defined as: 1) A doubling of platelet counts at the time point of maximum response (through Day 14) as compared to Day 0 AND an increase to an absolute level of ≥50,000/μL in participants with a baseline platelet count of &lt;50,000/μL, OR 2) A 50% increase in the platelet count at the time point of maximum response (through Day 14) as compared to Day 0 in participants with a baseline platelet count of ≥50,000/μL. The analysis was specified only for participants with ITP (Part 2) that received treatment with MK-8723 or matching placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve of MK-8723 From Time 0 to Infinity (AUC0-∞) Among Healthy Participants and Participants With ITP</measure>
    <time_frame>All dose groups: Predose and 4 (end of infusion), 6, 12, 24 hrs postdose and Days 3, 4, 5, 7, 10, 14, 21, 28; 30 mg/kg and 100 mg/kg dose groups: Days 43, 56, 71, 84</time_frame>
    <description>AUC0-∞ is a measure of total body exposure to drug. Serum samples for determination of AUC0-∞ were collected at pre-specified time-points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of MK-8723 Among Healthy Participants and Participants With ITP</measure>
    <time_frame>All dose groups: Predose and 4 (end of infusion), 6, 12, 24 hrs postdose and Days 3, 4, 5, 7, 10, 14, 21, 28; 30 mg/kg and 100 mg/kg dose groups: Days 43, 56, 71, 84</time_frame>
    <description>Serum samples for determination of Cmax were collected at pre-specified time-points.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Immune Thrombocytopenia Purpura</condition>
  <arm_group>
    <arm_group_label>Part 1: MK-8723 1 mg/kg in Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: MK-8723 3 mg/kg in Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: MK-8723 10 mg/kg in Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: MK-8723 30 mg/kg in Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: MK-8723 100 mg/kg in Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Matching Placebo to MK-8723</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MK-8723 10 mg/kg in ITP Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MK-8723 30 mg/kg in ITP Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MK-8723 100 mg/kg in ITP Participants</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Matching Placebo to MK-8723</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8723</intervention_name>
    <description>MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.</description>
    <arm_group_label>Part 1: MK-8723 1 mg/kg in Healthy Participants</arm_group_label>
    <arm_group_label>Part 1: MK-8723 3 mg/kg in Healthy Participants</arm_group_label>
    <arm_group_label>Part 1: MK-8723 10 mg/kg in Healthy Participants</arm_group_label>
    <arm_group_label>Part 1: MK-8723 30 mg/kg in Healthy Participants</arm_group_label>
    <arm_group_label>Part 1: MK-8723 100 mg/kg in Healthy Participants</arm_group_label>
    <arm_group_label>Part 2: MK-8723 10 mg/kg in ITP Participants</arm_group_label>
    <arm_group_label>Part 2: MK-8723 30 mg/kg in ITP Participants</arm_group_label>
    <arm_group_label>Part 2: MK-8723 100 mg/kg in ITP Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.</description>
    <arm_group_label>Part 1: Matching Placebo to MK-8723</arm_group_label>
    <arm_group_label>Part 2: Matching Placebo to MK-8723</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Part 1):

          -  Female participants must be non-pregnant, non-breast feeding, and of non-childbearing
             potential

          -  Has a Body Mass Index (BMI) &lt;=32 kg/m^2

          -  Has a body weight &gt;= 50 kg and &lt;= 100 kg

          -  Has been judged to be in good health based on medical history, physical examination,
             vital sign measurements, electrocardiogram (ECG), and laboratory safety tests

          -  Non-smoker or has not used nicotine or nicotine-containing products for at least 3
             months

        Inclusion Criteria (Part 2):

          -  Has been diagnosed with ITP at least 3 months prior

          -  Female ITP participants must be non-pregnant, non-breast feeding, and either of 1)
             non-childbearing potential or 2) must have serum beta human chorionic gonadotropin
             (HCG) level consistent with a non-pregnant state, and agree to use acceptable
             contraception from pretrial period until 84 days postdose

          -  Has a BMI &lt;=36 kg/m^2

          -  Has been judged to be in good health, other than ITP diagnosis, based on medical
             history, physical examination, vital sign measurements, ECG, and laboratory safety
             tests

        Exclusion Criteria (Part 1):

          -  Has a history or clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological, renal, respiratory, genitourinary, or major
             neurological abnormalities or diseases

          -  Has a history of cancer (malignancy)

          -  Has a history of significant multiple and/or severe allergies or has had an
             anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies, or human
             immunodeficiency virus (HIV)

          -  Has had major surgery or donated or lost 1 unit of blood in the 4 weeks prior

          -  Has participated in another investigational trial within 4 weeks (12 weeks for
             biologics)

          -  Has received a live virus vaccination within 42 days or plans to receive such while
             participating in the trial

          -  Is unable to refrain from or anticipates the use of any medication, including
             prescription and non-prescription drugs and herbal remedies from 2 weeks prior and for
             the duration of the trial

          -  Consumes greater than 3 glasses of alcoholic beverages per day

          -  Consumes greater than 6 servings of caffeine-containing beverages per day

          -  Is currently a regular user of any illicit drugs or has a history of drug and/or
             alcohol abuse within 3 months

          -  Has a history of ITP or other autoimmune disease

          -  Has an active infection that is clinically significant

        Exclusion Criteria (Part 2):

          -  Has a comorbid and significant hematological or immunological disorder

          -  Has a history of significant multiple and/or severe allergies or has had an
             anaphylactic reaction or significant intolerability to prescription or
             non-prescription drugs or food

          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies, or HIV

          -  Has had major surgery or donated or lost 1 unit of blood within 4 weeks

          -  Has participated in another investigational trial within 4 weeks (12 weeks for
             biologics), excluding prior participation in the current study

          -  Has a history of ITP unresponsive to intravenous immunoglobulin (IVIG)

          -  Has had systemic corticosteroid use within 1 month (with the exception of stable low
             dose oral corticosteroids)

          -  Has had systemic IVIG or other systemic immunomodulatory therapy, excluding MK-8723
             administration in the current study, within 3 months

          -  Has received a thrombopoietin receptor antagonist within 3 months

          -  Is unable to refrain from using thrombopoietin receptor agonists and/or systemic
             immune modulatory medications throughout the study

          -  Has received a live virus vaccine within 42 days prior or plans to receive such during
             the trial

          -  Consumes greater than 3 alcoholic beverages per day

          -  Consumes greater than 6 servings of caffeine-containing beverages per day

          -  Is currently a regular user of any illicit drugs or has a history of drug and/or
             alcohol abuse within 3 months

          -  Has clinical evidence of bleeding or coagulopathy including petechial rash, easy
             bruising, or excessive gingival bleeding with routine dental hygiene

          -  Has an active infection that is clinically significant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Georgia</country>
    <country>Israel</country>
    <country>Moldova, Republic of</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2013</study_first_submitted>
  <study_first_submitted_qc>October 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <results_first_submitted>January 31, 2017</results_first_submitted>
  <results_first_submitted_qc>January 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 21, 2017</results_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Amendment 3 specified a re-enrollment procedure for eligible participants in Part 2 to participate in more than one dosing panel.</recruitment_details>
      <pre_assignment_details>2 participants that completed Part 2 10 mg/kg were re-enrolled in Part 2 100 mg/kg &amp; dosed. Both participants completed Part 2 100 mg/kg. 1 participant originally assigned to Part 2 30 mg/kg received placebo in error &amp; is included in Part 2 Placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: MK-8723 1 mg/kg in Healthy Participants</title>
          <description>MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: MK-8723 3 mg/kg in Healthy Participants</title>
          <description>MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1: MK-8723 10 mg/kg in Healthy Participants</title>
          <description>MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1: MK-8723 30 mg/kg in Healthy Participants</title>
          <description>MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="P5">
          <title>Part 1: MK-8723 100 mg/kg in Healthy Participants</title>
          <description>MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="P6">
          <title>Part 1: Matching Placebo to MK-8723</title>
          <description>Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="P7">
          <title>Part 2: MK-8723 10 mg/kg in ITP Participants</title>
          <description>MK-8723 10 mg/kg administered as a single IV infusion to participants with immune thrombocytopenia purpura (ITP) in Part 2. 2 participants were subsequently enrolled in Part 2 MK-8723 100 mg/kg.</description>
        </group>
        <group group_id="P8">
          <title>Part 2: MK-8723 30 mg/kg in ITP Participants</title>
          <description>MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
        </group>
        <group group_id="P9">
          <title>Part 2: MK-8723 100 mg/kg in ITP Participants</title>
          <description>MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants with ITP from Part 2 MK-8723 10 mg/kg were re-enrolled into Part 2 100 mg/kg and dosed (not shown).</description>
        </group>
        <group group_id="P10">
          <title>Part 2: Matching Placebo to MK-8723</title>
          <description>Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are presented for all participants that enrolled in the study according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg and dosed per protocol procedure.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1: MK-8723 1 mg/kg in Healthy Participants</title>
          <description>MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: MK-8723 3 mg/kg in Healthy Participants</title>
          <description>MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1: MK-8723 10 mg/kg in Healthy Participants</title>
          <description>MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1: MK-8723 30 mg/kg in Healthy Participants</title>
          <description>MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="B5">
          <title>Part 1: MK-8723 100 mg/kg in Healthy Participants</title>
          <description>MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="B6">
          <title>Part 1: Matching Placebo to MK-8723</title>
          <description>Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="B7">
          <title>Part 2: MK-8723 10 mg/kg in ITP Participants</title>
          <description>MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.</description>
        </group>
        <group group_id="B8">
          <title>Part 2: MK-8723 30 mg/kg in ITP Participants</title>
          <description>MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
        </group>
        <group group_id="B9">
          <title>Part 2: MK-8723 100 mg/kg in ITP Participants</title>
          <description>MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.</description>
        </group>
        <group group_id="B10">
          <title>Part 2: Matching Placebo to MK-8723</title>
          <description>Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="2"/>
            <count group_id="B9" value="3"/>
            <count group_id="B10" value="4"/>
            <count group_id="B11" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" spread="2.7"/>
                    <measurement group_id="B2" value="32.7" spread="13.0"/>
                    <measurement group_id="B3" value="31.0" spread="12.2"/>
                    <measurement group_id="B4" value="25.7" spread="4.2"/>
                    <measurement group_id="B5" value="32.7" spread="10.5"/>
                    <measurement group_id="B6" value="30.1" spread="9.5"/>
                    <measurement group_id="B7" value="38.7" spread="22.3"/>
                    <measurement group_id="B8" value="53.0" spread="4.2"/>
                    <measurement group_id="B9" value="38.3" spread="22.7"/>
                    <measurement group_id="B10" value="50.3" spread="13.5"/>
                    <measurement group_id="B11" value="33.2" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing an Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 84 days</time_frame>
        <population>The All Participants as Treated (APaT) population consisting of all participants who received at least one dose of study drug was used for the safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: MK-8723 1 mg/kg in Healthy Participants</title>
            <description>MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: MK-8723 3 mg/kg in Healthy Participants</title>
            <description>MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: MK-8723 10 mg/kg in Healthy Participants</title>
            <description>MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: MK-8723 30 mg/kg in Healthy Participants</title>
            <description>MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: MK-8723 100 mg/kg in Healthy Participants</title>
            <description>MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Matching Placebo to MK-8723</title>
            <description>Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: MK-8723 10 mg/kg in ITP Participants</title>
            <description>MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: MK-8723 30 mg/kg in ITP Participants</title>
            <description>MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: MK-8723 100 mg/kg in ITP Participants</title>
            <description>MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: Matching Placebo to MK-8723</title>
            <description>Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing an Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>The All Participants as Treated (APaT) population consisting of all participants who received at least one dose of study drug was used for the safety analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Discontinuing Study Due to an Adverse Event (AE)</title>
        <description>An AE is defined as any unfavorable and unintended medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 84 Days</time_frame>
        <population>The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: MK-8723 1 mg/kg in Healthy Participants</title>
            <description>MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: MK-8723 3 mg/kg in Healthy Participants</title>
            <description>MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: MK-8723 10 mg/kg in Healthy Participants</title>
            <description>MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: MK-8723 30 mg/kg in Healthy Participants</title>
            <description>MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: MK-8723 100 mg/kg in Healthy Participants</title>
            <description>MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: Matching Placebo to MK-8723</title>
            <description>Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: MK-8723 10 mg/kg in ITP Participants</title>
            <description>MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: MK-8723 30 mg/kg in ITP Participants</title>
            <description>MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: MK-8723 100 mg/kg in ITP Participants</title>
            <description>MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: Matching Placebo to MK-8723</title>
            <description>Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing Study Due to an Adverse Event (AE)</title>
          <description>An AE is defined as any unfavorable and unintended medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Positive Platelet Response to MK-8723</title>
        <description>In participants with ITP, platelet response is a rapid, sensitive, and highly qualitative measure of response to anti-inflammatory therapy. A positive platelet response was defined as: 1) A doubling of platelet counts at the time point of maximum response (through Day 14) as compared to Day 0 AND an increase to an absolute level of ≥50,000/μL in participants with a baseline platelet count of &lt;50,000/μL, OR 2) A 50% increase in the platelet count at the time point of maximum response (through Day 14) as compared to Day 0 in participants with a baseline platelet count of ≥50,000/μL. The analysis was specified only for participants with ITP (Part 2) that received treatment with MK-8723 or matching placebo.</description>
        <time_frame>Up to Day 14</time_frame>
        <population>The per protocol population consisting of all participants in compliance with the protocol (e.g., availability of measurements, absence of major protocol violations) was used for the pharmacodynamic (platelet response) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: MK-8723 10 mg/kg in ITP Participants</title>
            <description>MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: MK-8723 30 mg/kg in ITP Participants</title>
            <description>MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: MK-8723 100 mg/kg in ITP Participants</title>
            <description>MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: Matching Placebo to MK-8723</title>
            <description>Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive Platelet Response to MK-8723</title>
          <description>In participants with ITP, platelet response is a rapid, sensitive, and highly qualitative measure of response to anti-inflammatory therapy. A positive platelet response was defined as: 1) A doubling of platelet counts at the time point of maximum response (through Day 14) as compared to Day 0 AND an increase to an absolute level of ≥50,000/μL in participants with a baseline platelet count of &lt;50,000/μL, OR 2) A 50% increase in the platelet count at the time point of maximum response (through Day 14) as compared to Day 0 in participants with a baseline platelet count of ≥50,000/μL. The analysis was specified only for participants with ITP (Part 2) that received treatment with MK-8723 or matching placebo.</description>
          <population>The per protocol population consisting of all participants in compliance with the protocol (e.g., availability of measurements, absence of major protocol violations) was used for the pharmacodynamic (platelet response) analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve of MK-8723 From Time 0 to Infinity (AUC0-∞) Among Healthy Participants and Participants With ITP</title>
        <description>AUC0-∞ is a measure of total body exposure to drug. Serum samples for determination of AUC0-∞ were collected at pre-specified time-points.</description>
        <time_frame>All dose groups: Predose and 4 (end of infusion), 6, 12, 24 hrs postdose and Days 3, 4, 5, 7, 10, 14, 21, 28; 30 mg/kg and 100 mg/kg dose groups: Days 43, 56, 71, 84</time_frame>
        <population>The per protocol population consisting of all participants in compliance with the protocol (e.g., availability of measurements, absence of major protocol violations) was used for the pharmacokinetic (AUC0-∞) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: MK-8723 1 mg/kg in Healthy Participants</title>
            <description>MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: MK-8723 3 mg/kg in Healthy Participants</title>
            <description>MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: MK-8723 10 mg/kg in Healthy Participants</title>
            <description>MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: MK-8723 30 mg/kg in Healthy Participants</title>
            <description>MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: MK-8723 100 mg/kg in Healthy Participants</title>
            <description>MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: MK-8723 10 mg/kg in ITP Participants</title>
            <description>MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: MK-8723 30 mg/kg in ITP Participants</title>
            <description>MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: MK-8723 100 mg/kg in ITP Participants</title>
            <description>MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of MK-8723 From Time 0 to Infinity (AUC0-∞) Among Healthy Participants and Participants With ITP</title>
          <description>AUC0-∞ is a measure of total body exposure to drug. Serum samples for determination of AUC0-∞ were collected at pre-specified time-points.</description>
          <population>The per protocol population consisting of all participants in compliance with the protocol (e.g., availability of measurements, absence of major protocol violations) was used for the pharmacokinetic (AUC0-∞) analysis.</population>
          <units>hr*μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4830" spread="22.1"/>
                    <measurement group_id="O2" value="22300" spread="21.9"/>
                    <measurement group_id="O3" value="65800" spread="13.4"/>
                    <measurement group_id="O4" value="186000" spread="7.28"/>
                    <measurement group_id="O5" value="711000" spread="50.5"/>
                    <measurement group_id="O6" value="66200" spread="57.9"/>
                    <measurement group_id="O7" value="203000" spread="22.6"/>
                    <measurement group_id="O8" value="668000" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) of MK-8723 Among Healthy Participants and Participants With ITP</title>
        <description>Serum samples for determination of Cmax were collected at pre-specified time-points.</description>
        <time_frame>All dose groups: Predose and 4 (end of infusion), 6, 12, 24 hrs postdose and Days 3, 4, 5, 7, 10, 14, 21, 28; 30 mg/kg and 100 mg/kg dose groups: Days 43, 56, 71, 84</time_frame>
        <population>The per protocol population consisting of all participants in compliance with the protocol (e.g., availability of measurements, absence of major protocol violations) was used for this pharmacokinetic (Cmax) analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: MK-8723 1 mg/kg in Healthy Participants</title>
            <description>MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: MK-8723 3 mg/kg in Healthy Participants</title>
            <description>MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: MK-8723 10 mg/kg in Healthy Participants</title>
            <description>MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: MK-8723 30 mg/kg in Healthy Participants</title>
            <description>MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: MK-8723 100 mg/kg in Healthy Participants</title>
            <description>MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: MK-8723 10 mg/kg in ITP Participants</title>
            <description>MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: MK-8723 30 mg/kg in ITP Participants</title>
            <description>MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: MK-8723 100 mg/kg in ITP Participants</title>
            <description>MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of MK-8723 Among Healthy Participants and Participants With ITP</title>
          <description>Serum samples for determination of Cmax were collected at pre-specified time-points.</description>
          <population>The per protocol population consisting of all participants in compliance with the protocol (e.g., availability of measurements, absence of major protocol violations) was used for this pharmacokinetic (Cmax) analysis.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="11.4"/>
                    <measurement group_id="O2" value="72.3" spread="8.53"/>
                    <measurement group_id="O3" value="225" spread="15.5"/>
                    <measurement group_id="O4" value="844" spread="12.2"/>
                    <measurement group_id="O5" value="2160" spread="23.9"/>
                    <measurement group_id="O6" value="195" spread="11.7"/>
                    <measurement group_id="O7" value="741" spread="24.8"/>
                    <measurement group_id="O8" value="2450" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 84 days</time_frame>
      <desc>The APaT population consisting of all participants who received at least one dose of study drug was used for the safety analysis. AEs are presented according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg &amp; dosed per protocol procedure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: MK-8723 1 mg/kg in Healthy Participants</title>
          <description>MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: MK-8723 3 mg/kg in Healthy Participants</title>
          <description>MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: MK-8723 10 mg/kg in Healthy Participants</title>
          <description>MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: MK-8723 30 mg/kg in Healthy Participants</title>
          <description>MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="E5">
          <title>Part 1: MK-8723 100 mg/kg in Healthy Participants</title>
          <description>MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="E6">
          <title>Part 1: Matching Placebo to MK-8723</title>
          <description>Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.</description>
        </group>
        <group group_id="E7">
          <title>Part 2: MK-8723 10 mg/kg in ITP Participants</title>
          <description>MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2. 2 participants subsequently enrolled in Part 2 MK-8723 100 mg/kg.</description>
        </group>
        <group group_id="E8">
          <title>Part 2: MK-8723 30 mg/kg in ITP Participants</title>
          <description>MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.</description>
        </group>
        <group group_id="E9">
          <title>Part 2: MK-8723 100 mg/kg in ITP Participants</title>
          <description>MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2. This group includes 2 participants that re-enrolled from Part 2 MK-8723 10 mg/kg.</description>
        </group>
        <group group_id="E10">
          <title>Part 2: Matching Placebo to MK-8723</title>
          <description>Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

